17347-29-4

Basic information

• Product Name: Benzene, 1-bromo-3-[(2,2-diethoxyethyl)thio]-
• CAS NO: 17347-29-4
• Molecular Formula: C12H17BrO2S
• Molecular Weight: 305.236
• Mol File: 17347-29-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzene, 1-bromo-3-[(2,2-diethoxyethyl)thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-3-[(2,2-diethoxyethyl)thio]-(17347-29-4)
• EPA Substance Registry System: Benzene, 1-bromo-3-[(2,2-diethoxyethyl)thio]-(17347-29-4)

Safety Data

• Hazardous Substances Data: 17347-29-4(Hazardous Substances Data)

Upstream product

• 591-19-5 m-Bromoaniline 
• 6320-01-0 3-Bromothiophenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 1709825-02-4 6-bromo-2-(trifluoromethyl)benzo[b]thiophene 
• 6386-80-7 benzo[b]thiophene-6-carbaldehyde 
• 6179-28-8 benzothiophene-6-methanol 
• 6179-26-6 benzo[b]thiophene-6-carboxylic acid 
• 154650-81-4 benzo[b]thiophene-6-carbonitrile 
• 17347-32-9 6-bromobenzothiophene 
• 5118-13-8 4-bromobenzo[b]thiophene 

Relevant articles and documents

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES

Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced directly or indirectly by mutation or frameshift.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.